A Group of Promising Proteins - Cell Cycle Markers
A Group of Promising Proteins - Cell Cycle MarkersMost eukaryotic cells depends on an internal clock for survival; they proceed through a sequential event known as the cell cycle . The cell cycle allows multicellular organisms to grow and divide and single-celled or...
Detailed information

The Oncogene HER2: a New Target for Drug-Resistant Tumors
The Oncogene HER2: a New Target for Drug-Resistant TumorsOn March 17, 2021, a research paper entitled "Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors" [1] has attracted attention. Researchers found that the combination of MCL-1 inh...
Detailed information

NRG1 or NRG1 Fusions: an Intriguing Therapeutic Target in Diseases
NRG1 or NRG1 Fusions: an Intriguing Therapeutic Target in DiseasesOn January 7, 2021, the US FDA has granted a fast track designation to Zenocutuzumab (MCLA-128) as a potential therapeutic option for patients with metastatic solid tumors harboring NRG1 gene fusions. Early, Journal of T...
Detailed information

TNFR1: A Multifaceted Molecule in Cancer, Another Promising Therapeutic Target for COVID-19
TNFR1: A Multifaceted Molecule in Cancer, Another Promising Therapeutic Target for COVID-19On January 7, 2021, a study published in the journal Cancer Research showed that TNFR1-mediated apoptosis and necrosis are associated with leukemia [1]. TNFR1, as an emerging biological target, numerous studies confirm ...
Detailed information

Neutralizing Antibody Stands Out Among Antiviral Therapies
Neutralizing Antibody Stands Out Among Antiviral TherapiesHuman has been constantly struggling with various diseases from the birth. Human history documented several brutal, disastrous, and deadly diseases, such as smallpox, bubonic plague, cholera, and influenza. They broke ou...
Detailed information

MUC16 (CA125): a Promising Predictive Marker and Therapeutic Target in Cancer
MUC16 (CA125): a Promising Predictive Marker and Therapeutic Target in CancerOn November 9, 2020, Quest PharmaTech Inc. announced that Oregovomab, a MUC16 monoclonal antibody, has been dosed in the patients with ovarian cancer in phase III clinical trial. It means that targeting MUC16 drugs w...
Detailed information

ERBB3/HER3: a New Target for Tumor Therapy, a Driver Gene of Multi-Tumors
ERBB3/HER3: a New Target for Tumor Therapy, a Driver Gene of Multi-TumorsRecently, a study published in the journal Protein & Cell (impact factor: 10.164), attracted attention. The research found that ERBB3 mutation were closely related to tumor tolerance, and further revealed that anti-ERBB3...
Detailed information

Non-Hodgkin's Lymphoma, One of Common Heterogeneous Malignant Tumors
Non-Hodgkin's Lymphoma, One of Common Heterogeneous Malignant TumorsLymphoma is the most common of heterogeneous malignant tumors caused by malignant transformation of lymphocytes. Such tumors usually originate from the lymph nodes or other lymphatic tissues. From the 1970s to the 1990s,...
Detailed information

Multiple Myeloma, One of High-Risk Factors for COVID-19
Multiple Myeloma, One of High-Risk Factors for COVID-19Accumulating studies have reported that among the people who face the greatest harm from COVID-19 (the disease caused by the SARS-CoV-2) are people with cancer [1]. And among those who have cancer, blood cancers like mul...
Detailed information

STAT3: a Key Transcriptional Regulator in Cancer
STAT3: a Key Transcriptional Regulator in CancerSignal transducer and activator of transcription 3 (STAT3) is a latent cytoplasmic transcription factor [1]. It is interesting that STAT3 was discovered because of its role in the acute-phase response, which is the only ...
Detailed information

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1

Wait!

Join the 25,000 subscribers to get research hotpots, technical tips, latest information on events, sales and offers.

Sign up now!

We don't deal in spam.